July 23, 2007

PTO/SB/08A (04-07) Approved for use through 09/30/2007, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO Application Number 10/580,512 Filing Date May 23, 2006 INFORMATION DISCLOSURE First Named Inventor Ichikawa, Yoshitaka STATEMENT BY APPLICANT Art Unit 1614 (Use as many sheets as necessary) Examiner Name TBA Attorney Docket Number 8031-013-US of 4

Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	Cite No.1	Number-Kind Code ^{2 (# known)}	MIM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevan Figures Appear
/EW/		US-3,683,076	08-08-1972		
/EW/		^{US-} 4,870,061	09-26-1989		
/EW/		^{US-} 5,840,715	11-24-1998		
/EW/		^{US-} 6,136,795	10-24-2000		·
		US-		•	
		US-			·
		US-			
		US-			·
		US-			

•		FORE	IGN PATENT DOCUI	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	Т
/EW/		PCT/US02/09859	10-10-2002			
						L
						L
						L

Examiner	1990	Date	
Signature	/Everett White/	Considered	08/12/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3), ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
a collection of information unless it contains a valid OMB

	ite for form 1449/PTO			e required to respond to a conection	Complete if Known			
Cabana	101011011111111111111111111111111111111			Application Number	10/580,512			
INF	ORMATION	DIS	CLOSURE	Filing Date	May 23, 2006			
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Ichikawa, Yoshitaka			
	(lice as many sho	ate ac	accessor/	Art Unit	1614	-		
(Use as many sheets as necessary)				Examiner Name	TBA			
Sheet	2	of	4	Attorney Docket Number	8031-013-US			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/EW/	-	ALTMAN, R. D., et al., "Practice Guidelines in the Management of Osteoarthritis," Osteoarthritis and Cartilage, (1998), 6(Supp.A):22-24.	
000000000000000000000000000000000000000	000000000000000000000000000000000000000	BOHNE, W., "Glukosamine In Der Konsorvativen Arthrosebehandlung," Med Welt. Nr., (1969), 30:1668-1671.	000000000000000000000000000000000000000
/EW/	•	CHU, S. C., et al., "Analysis of the Cytokin-Stimulated Human Inducible Nitric Oxide Synthase (iNOS) Gene," Biochem. Biophys. Res. Commun., (1998), 248:871-878.	
/EW/		CHOU, T., et al., "Glycosylation of the c-Myc transactivation domain," Proc. Natl. Acad. Sci. USA, (1995), 92:4417-4421.	
/EW/		DE VRIES, B. J., et al., "Quantitation of glycosaminoglycan metabolism in anatomically intact articular cartilage of the mouse", Rheumatol. Int. (1986) 6,6:273-281.	
500000000000000000000000000000000000000	000000000000000000000000000000000000000	DIEPPE, P., "Molecular Markers for Joint and Skoletal Diseases: Notes from the General Discussion," Acta. Orthop. Scand., (1995), 66(Supp.266):211-212.	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
	***************************************	FINGL, E. et al., "The Pharmacological Basis of Therapeutics," (1975), Chapter 1:1-46.	
/EW/		GABRIEL, S. E., et al, "Direct Medical Costs Unique to People with Arthritis," J. Rheumatol., (1997), 24:719-725.	
/EW/		GENG, Y., et al., "Tyrosine Kinases Are Involved With the Expression of Inducible Nitric Oxide Synthase in Human Articular," J. Cell. Physiol., (1995), 163:545-554.	
/EW/		HALTIWANGER, R. S., et al., "O-Glycosylation of Nuclear and Cytoplasmic Proteins: Regulation Analogous," Biochem. Biophys. Res. Commun., (1997), 231:237-242.	

Examiner		Date	0040/0000
Signature	/Everett White/	Considered	08/10/2009

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. Do NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-07) Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO	Complete if Known		
- Substitute for form 1443/1 TO	Application Number	10/580,512	
INFORMATION DISCLOSURE	Filing Date	May 23, 2006	
STATEMENT BY APPLICANT	First Named Inventor	Ichikawa, Yoshitaka	
(lan an increase about an annual and	Art Unit	1614	
(Use as many sheets as necessary) _.	Examiner Name	ТВА	
Sheet 3 of 4	Attorney Docket Number	8031-013-US	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
/EW/		HEVEL, J. M., et al., "Nitric-Oxide Synthase Assays," Methods Enzymol., (1994), 233:250-258.	·
/EW/		HOCHBERG, M. C., et al., "Guidelines for the Medical Management of Osteoarthritis," Arthritis & Rheumatism, (1995), 38(11):1535-1546.	
/EW/		INEROT, S., et al., "Articular-Cartilage Proteoglycans in Aging and Osteoarthritis," Biochem. J., (1978), 169:143-156.	
/EW/	-	KORNFELD, S., et al., "The Feedback Control of Sugar Nucleotide Biosynthesis in Liver, " Proc. Natl. Acad. Sci. USA, (1964), 52:371-379.	
/EW/		KOLM-LITTY, J., et al., "High Glucose-induced Transforming Growth FactorB1 Production Is Mediated by the Hexosamine Pathway," J. Clin. Invest., (1998), 101(1):160-169.	
/EW/		KARIN, M., "The Beginning of the End: lkB Kinase (lKK) and NF-kB Activation," J. Biol. Chem., (1999), 274(39):27339-27342.	
/EW/		LAWRENCE, R. C., et al., "Estimates of the Prevalence of Arthritis and Selected Musculoskeletal Disorders," Arthritis & Rheumatism, (1998), 41(5):778-799.	
/EW/		LOZADA, C. J., et al., "Chondroprotection in Osteoarthritis," Bull. Rheum. Dis., (1997), 46(7):5-7.	
/EW/		MEVORACH, D., et al., "Osteoarthritis and Chondroprotection," Isr. J. Med. Sci., (1994), 30:928-931.	
/EW/		MARCH, L. M., et al., "Economics of Osteoarthritis: A Global Perspective," Balliere's Clinical Rheumatology, (1997), 11(4):817-834.	

Examiner	, y , y , y , y , y , y , y , y , y , y	• '	Date	22400000
Signature	/Everett White/		Considered	08/10/2009

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (04-07)

Approved for use through 09/30/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO		Complete if Known
	Application Number	10/580,512
INFORMATION DISCLOSURE	Filing Date	May 23, 2006
STATEMENT BY APPLICANT	First Named Inventor	Ichikawa, Yoshitaka
(Use as many sheets as necessary)	Art Unit	1614
(Ose as many sneets as necessary)	Examiner Name	ТВА
Sheet 4 of 4	Attorney Docket Number	8031-013-US

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/EW/		NEWTON, R., et al., "Superinduction of COX-2 mRNA By Cycloheximide and Interleukin-1B Involves Increased Transcription and Correlates," FEBS Letters, (1997), 418:135:138.	
/EW/		PARIKH, A. A., et al., "IL-6 Production in Human Intrestinal Epithelial Cells Following Stimulation with IL-1 B Is Associated," J. Clin. Research, (1997), 69:139-144.	
/EW/	-	SANDY, J. D., et al., "Chondrocyte-Mediated Catabolism of Aggrecan: Aggrecanase- Dependent Cleavage Induced by Interleukin-1," Biochem. J. (1998), 335:59-66.	
/EW/		SANDY, J. D., et al., "Chondrocyte-Mediated Catabolism of Aggrecan: Evidence for a Glycosylphosphatidylinositol-Linked," Arch. Biochem. Biophys. (1999), 367(2):258-264.	
	***************************************	SETNIKAR L et al. "Antireactive properties of Glucosamine Sulfate."	
		Arzneim-Forsch./Drug Res, (1991), 41(1):157-161.	
/EW/		SCHARSTUHL, A., et al., "Loss of Transforming Growth Factor Counteraction on Interleukin 1 Mediated Effects in Cartilage of Old Mice," Ann. Rheum. Dis., (2002), 61:1095-1098.	
-			

Examiner		Date	
Signature	/Everett White/	Considered	08/10/2009

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.